|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The incidence of <i>EGFR</i> T790M tended to be higher among patients with CNS PD than in those without CNS PD, although the difference was not statistically significant (66.7% <i>vs.</i> 40.4%; P=0.23).
|
31179076 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the real-world clinical adoption of the combination approach with both tissue rebiopsy and liquid biopsy for T790M genotyping may provide significant benefits to patients who have developed PD after first-generation TKI treatments.
|
30927306 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The presence of an EGFRm (excluding T790M) was associated with untreated or progressive disease, p = 0.04.
|
31027703 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Total duration of EGFR-TKI treatment before rebiopsy, TKI-free interval, EGFR-TKI treatment history immediately before rebiopsy, continuation of initial EGFR-TKI beyond progressive disease, progression-free survival after initial TKI treatment, and rebiopsy site (other than fluid samples) significantly influenced T790M status.
|
28866043 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Osimertinib was approved by the US Food & Drug Administration in November 2015 for patients whose tumors exhibited T790M mutation and for those with progressive disease on other EGFR TKIs.
|
28367058 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, the levels of the EGFR exon 19 deletion driver mutation and the T790M resistance mutation in the circulating tumor DNA continued to rise and the patient died from progressive disease 6 weeks after commencement of combination therapy.
|
28843359 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T790M was detected in 14/29 patients (48.3%) with a partial response to afatinib, 1/4 patients (25%) with stable disease, and 1/4 patients (25%) with progressive disease as the best response.
|
28978102 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of 4 of the 5 patients with a history of T790M positivity based on plasma DNA levels had PD.
|
28588734 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Almost half of the T790M ctDNA positive patients were identified at a median time of 2.2 months prior to clinically progressive disease (PD).
|
26867973 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dividing into four periods (before PD, at PD, at discontinuation of EGFR-TKI and subsequently), T790M was detected in 10, 19, 24 and 27% of patients, respectively.
|
26577492 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR T790M was identified from plasma DNA in 54% (15 of 28) of patients with prior clinical response to gefitinib/erlotinib, 29% (4 of 14) with prior stable disease, and in 0% (0 of 12) that had primary progressive disease or were untreated with gefitinib/erlotinib.
|
19351754 |
2009 |
|
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Here, we conducted a retrospective study to assess 375 patients whose initial biopsy indicated a TKI-sensitizing mutation (either EGFR 19del or L858R) and who developed PD after treatment with first-generation TKIs, and assayed for T790M status.
|
30927306 |
2019 |
|
rs1057519848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Here, we conducted a retrospective study to assess 375 patients whose initial biopsy indicated a TKI-sensitizing mutation (either EGFR 19del or L858R) and who developed PD after treatment with first-generation TKIs, and assayed for T790M status.
|
30927306 |
2019 |
|
rs121434568
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Here, we conducted a retrospective study to assess 375 patients whose initial biopsy indicated a TKI-sensitizing mutation (either EGFR 19del or L858R) and who developed PD after treatment with first-generation TKIs, and assayed for T790M status.
|
30927306 |
2019 |
|
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Patients with EGFR-activating mutations (del19 and L858R) that progressed using first-line gefitinib treatment were enrolled and treated with gefitinib beyond PD plus pemetrexed 500 mg/m<sup>2</sup> q3w.
|
30268482 |
2018 |
|
rs1057519848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Patients with EGFR-activating mutations (del19 and L858R) that progressed using first-line gefitinib treatment were enrolled and treated with gefitinib beyond PD plus pemetrexed 500 mg/m<sup>2</sup> q3w.
|
30268482 |
2018 |
|
rs121434568
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Patients with EGFR-activating mutations (del19 and L858R) that progressed using first-line gefitinib treatment were enrolled and treated with gefitinib beyond PD plus pemetrexed 500 mg/m<sup>2</sup> q3w.
|
30268482 |
2018 |
|
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Eight patients received an EGFR TKI: three cases with G719X plus another mutation had partial responses (PRs) to erlotinib; of three cases with L858R plus another mutation, two displayed PRs and one (with EGFR-L858R+A871G) progressive disease (PD) to erlotinib; one NSCLC with EGFR-L861Q+E709A and one with delL747_T751+R776S had PRs to EGFR TKIs.
|
23242437 |
2013 |
|
rs1057519848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Eight patients received an EGFR TKI: three cases with G719X plus another mutation had partial responses (PRs) to erlotinib; of three cases with L858R plus another mutation, two displayed PRs and one (with EGFR-L858R+A871G) progressive disease (PD) to erlotinib; one NSCLC with EGFR-L861Q+E709A and one with delL747_T751+R776S had PRs to EGFR TKIs.
|
23242437 |
2013 |
|
rs121434568
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Eight patients received an EGFR TKI: three cases with G719X plus another mutation had partial responses (PRs) to erlotinib; of three cases with L858R plus another mutation, two displayed PRs and one (with EGFR-L858R+A871G) progressive disease (PD) to erlotinib; one NSCLC with EGFR-L861Q+E709A and one with delL747_T751+R776S had PRs to EGFR TKIs.
|
23242437 |
2013 |
|
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
All 4 patients with progressive disease had a L858R mutation.
|
20430469 |
2011 |
|
rs1057519848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
All 4 patients with progressive disease had a L858R mutation.
|
20430469 |
2011 |
|
rs121434568
|
|
|
0.040 |
GeneticVariation |
BEFREE |
All 4 patients with progressive disease had a L858R mutation.
|
20430469 |
2011 |
|
rs1405999227
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Regarding the efficacy of anti-EGFR therapy, the patient with an I326V mutation had progressive disease (+115%) despite no genetic alterations detected in the EGFR pathway that could drive resistance, suggesting an alternate resistance mechanism.
|
30463788 |
2018 |
|
rs1057519861
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After 3 months of progression-free survival, he experienced progressive disease with emergence of EGFR C797S located in cis to T790M.
|
28662863 |
2017 |